Itchy Skin (Pruritus): Causes, Symptoms, Treatment & Prevention

Itchy skin, or pruritus, is a distinct cutaneous sensation that triggers an urge to scratch. It is mediated mainly by unmyelinated C-fibres in the epidermis and superficial dermis, with histamine driving classic urticarial itch and a non-histaminergic pathway (involving Mas-related G-protein receptors, IL-31, TSLP, opioid receptors and PAR-2) carrying chronic, neuropathic and systemic itch. Many of the antihistamine “failures” seen on the ward simply reflect a non-histaminergic mechanism that needs a different lever.

By international consensus, itch lasting under six weeks is acute and itch persisting at or beyond six weeks is chronic. The International Forum for the Study of Itch (IFSI) classifies chronic pruritus by clinical appearance—itch on inflamed skin (group I), itch on apparently normal skin (group II) and itch with chronic secondary scratch lesions such as prurigo nodularis (group III)—and by aetiologic category: dermatologic, systemic, neuropathic, psychogenic, mixed or undetermined. That two-axis framework keeps the workup focused: a patient with weeping eczematous plaques does not need a hepatology screen; a patient with normal skin and refractory night-time itch absolutely does.

Pruritus is not a benign nuisance once it lingers. Sleep disruption, mood disturbance, lichenification, secondary infection from scratching and quality-of-life decrement comparable to chronic pain are well documented in dermatology and palliative care literature, and the itch–scratch–itch cycle quickly becomes self-sustaining unless interrupted by both targeted therapy and barrier care.

Two complementary frameworks help bedside reasoning. The first sorts patients by what the skin looks like; the second sorts them by where the itch is generated. Most patients map onto a single bucket within minutes, and that mapping dictates which investigations are non-negotiable.

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Patients describe itch in many ways—stinging, crawling, prickling, burning, “a deep itch nothing can reach”—and those qualifiers are often diagnostic. Asking the patient to point to the worst sites, the time of day it peaks, and the modifiers (heat, water, exercise, stress, certain fabrics) usually shortens the differential before a single test is ordered.

Common adult presentation

• Diffuse itching that disturbs sleep, with associated insomnia and daytime fatigue.
• Linear excoriations, fingernail-deep scratch marks, and prurigo nodules in chronic cases—often the only clinical sign on otherwise normal skin.
• Lichenification (thickened, leathery skin with accentuated markings) on accessible sites: shins, forearms, occipital scalp, vulva, scrotum, ankles.
• Secondary hyperpigmentation from chronic rubbing, especially in skin of colour.
• Visible primary lesions when the cause is dermatologic—classic eczema patches, scaling psoriatic plaques, urticarial wheals (hives) or post-scratch erythematous rash.

Pattern-recognition clues

• Aquagenic itch within minutes of warm water without rash—polycythaemia vera until proven otherwise.
• Palms and soles itch worst at night with progressive jaundice—cholestatic pruritus (primary biliary cholangitis, intrahepatic cholestasis of pregnancy, drug-induced cholestasis).
• Itch dramatically worse at night with household contacts itching—scabies; look for burrows in finger webs, wrists, axillae, waist and genitalia.
• Brachioradial pruritus—itching, burning or stinging on the dorsolateral forearms, often UV-exposed and sun-related, with neuropathic features.
• Notalgia paraesthetica—well-localised itch and hyperpigmented patch on the medial scapula, classically neuropathic.
• Generalised itch with B-symptoms (drenching night sweats, fevers, weight loss, lymphadenopathy)—suspect Hodgkin or non-Hodgkin lymphoma.

Atypical and easy-to-miss patterns

Older adults often present with isolated nocturnal itch and minimal visible disease—xerosis cutis (dry skin) in the over-65s is genuinely common but should not become the default diagnosis until systemic causes have been excluded. Patients on dialysis frequently understate symptoms because they have learned to tolerate them; ask explicitly. Pregnant patients in the third trimester may dismiss itchy palms as “nerves” when intrahepatic cholestasis is brewing. And patients with cognitive impairment may show only restlessness, scratch wounds and unexplained agitation.

The differential is wide but follows the IFSI buckets cleanly. A focused history (onset, duration, distribution, modifiers, drug list, systemic symptoms) plus a head-to-toe skin examination usually narrows it within a single visit.

Dermatologic causes

• Atopic dermatitis / atopic eczema: dominant cause of inflammatory itch in children and young adults; flexural pattern, family or personal atopic history.
• Urticaria: transient wheals lasting under 24 hours; chronic spontaneous urticaria when symptoms persist beyond 6 weeks.
• Psoriasis: well-demarcated scaly plaques; itch prominent in 60–90% despite the older textbook framing as “non-itchy”.
• Scabies and other infestations: burrows, nocturnal predominance, contact tracing; head lice, bedbugs and pediculosis pubis follow distinct distributions.
• Contact dermatitis (allergic and irritant): geometric distribution matching exposure (jewellery, fragrance, plants, occupational chemicals).
• Other inflammatory dermatoses: seborrhoeic dermatitis, lichen planus, lichen sclerosus, dermatitis herpetiformis (gluten-related, intensely itchy vesicles on extensors).
• Skin infections: folliculitis, tinea (including jock itch), candidiasis intertrigo, shingles prodrome.
• Xerosis cutis: low-grade chronic itch in older adults, exacerbated by central heating, harsh soaps and over-washing.
• Bullous pemphigoid: intense itch in older adults before the tense bullae appear—do not dismiss.

Systemic causes

• Cholestasis: primary biliary cholangitis, primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, drug-induced cholestasis, biliary obstruction from gallstones or pancreatic head tumour.
• Chronic liver disease: cirrhosis, hepatitis C, hepatitis B, alcoholic hepatitis and acute viral hepatitis A.
• Renal: chronic kidney disease stage 4–5 and dialysis-associated pruritus (CKD-aP).
• Endocrine: hypothyroidism, Hashimoto thyroiditis, Graves disease (paradoxical itch), type 2 diabetes with neuropathic or candidal contributions.
• Haematologic: iron deficiency anaemia, polycythaemia vera (aquagenic), Hodgkin and non-Hodgkin lymphoma, mastocytosis.
• Malignancy: paraneoplastic itch with hepatobiliary cancer, pancreatic, gynaecologic and lymphoproliferative tumours; cutaneous T-cell lymphoma when chronic erythematous patches accompany the itch.
• Infection: allergic disease spectrum, parasitic infections (onchocerciasis, schistosomiasis), HIV-associated pruritus and eosinophilic folliculitis in advanced HIV.

Neuropathic and psychogenic causes

• Brachioradial pruritus, notalgia paraesthetica, scalp dysesthesia: nerve-territory itch responsive to gabapentinoids and topical capsaicin or local anaesthetic.
• Post-herpetic itch: persistent dermatomal itch after shingles, often coexisting with neuralgia.
• Central neurologic disease: multiple sclerosis demyelinating itch; central post-stroke itch.
• Psychogenic and somatoform: delusional infestation (Ekbom syndrome), severe anxiety, depression, anxiety disorders; often overlap with fibromyalgia or Sjögren syndrome.

Drug-induced itch (high-yield)

• Opioids (morphine, codeine, oxycodone, neuraxial opioids—worse with intrathecal route).
• ACE inhibitors and ARBs—itch may be the only feature for months.
• Hydroxyethyl starch—delayed itch persisting up to a year after exposure.
• Allopurinol and other anti-gout agents (with rash—watch for SCAR).
• Beta-lactam antibiotics, sulfonamides, vancomycin (red-man syndrome), doxycycline.
• Statins, calcium channel blockers, thiazide diuretics, oral contraceptives.
• Anti-tuberculosis medications, especially rifampin (itch-without-rash even at therapeutic doses).
• Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) producing immune-related cutaneous adverse events.
• Biologics (monoclonal antibodies) and targeted oncology agents.

The clinical workup is structured around two questions: is the skin itself the problem? and if not, which organ system is? A thorough skin and nodal examination plus a focused systems screen usually decides the next investigation set; reflex panels prevent under-investigation when itch is on apparently normal skin.

Bedside history checklist

• Duration (acute vs ≥6 weeks chronic), onset pattern, daily timing (nocturnal predominance, post-shower).
• Distribution (focal vs generalised; specific sites such as palms/soles, scalp, anogenital, dermatomal patches).
• Modifiers: heat, water exposure, sweating, exercise, alcohol, stress, specific clothing or jewellery.
• Associated systemic symptoms: weight loss, night sweats, jaundice, fatigue, polyuria, polydipsia, cold intolerance, menstrual change.
• Drug timeline including over-the-counter, herbal, recreational and recent IV contrast or perioperative agents.
• Travel history, sexual exposures, pet and freshwater exposure, occupational and hobby chemicals.
• Mood, sleep, anxiety screening; impact on daily function and relationships.

Skin and lymphatic examination

Begin with a full-body screen using a structured skin assessment—light it well, expose all sites including web spaces, scalp, axillae, anogenital area and feet, and document primary versus secondary lesions separately. Pair it with a head-to-toe assessment to look for jaundice, palpable cervical/axillary/inguinal lymphadenopathy, splenomegaly, thyroid enlargement, peripheral oedema and goitre.

Baseline laboratory panel for chronic itch

• Full blood count with differential via a complete blood count—anaemia, eosinophilia, raised haematocrit pointing to polycythaemia.
• Renal panel via a comprehensive metabolic panel with eGFR and calcium for uraemic and hypercalcaemic itch.
• Liver function tests via LFTs with bilirubin and alkaline phosphatase; reflex ALT and AST patterns guide cholestatic versus hepatocellular drivers.
• Iron studies with ferritin—iron deficiency itch responds to repletion.
• Thyroid function via TSH with reflex free T4.
• Glycaemic screen with fasting glucose or HbA1c.
• HIV serology with appropriate counselling; consider hepatitis B and C surface markers.
• Inflammatory markers (ESR, CRP) and LDH if lymphoma is in the differential; serum tryptase if mastocytosis suspected; bile acids in pregnancy.
• Chest radiograph via a chest X-ray when lymphoma, sarcoidosis or paraneoplastic itch is suspected.

Targeted investigations

A skin biopsy with histology and direct immunofluorescence helps when bullous pemphigoid, dermatitis herpetiformis, cutaneous lymphoma or interface dermatitis are on the differential. Patch testing identifies allergic contact dermatitis when distribution suggests exposure. Dermoscopy can confirm scabies (the classic “delta-wing” mite at the burrow tip). Specialist tests—total IgE, specific IgE panels, JAK2 V617F for polycythaemia, antimitochondrial antibodies for primary biliary cholangitis—are added when first-pass screening points the way.

Common interpretation traps

• Normal LFTs do not exclude cholestasis. Bile acids may be raised before alkaline phosphatase rises, especially in pregnancy.
• Iron deficiency itch can occur without anaemia. A low ferritin alone justifies repletion.
• One normal antihistamine response does not rule out urticaria. Chronic spontaneous urticaria may need fourfold updosing of second-generation H1 blockers under specialist guidance.
• Dermographism is itchy. Skin writes a wheal where stroked—often missed when only a generic “rash” is documented.
• Crusted scabies looks like psoriasis. Trial of high-potency topical steroids worsens it dramatically.

A pragmatic chain that ward and primary-care teams can apply on first contact:

1. Is this acute (<6 weeks) or chronic (≥6 weeks)? Acute itch usually has an obvious trigger (drug, infection, contact); chronic itch needs the structured workup.
2. Is there a primary skin lesion? Group I (inflamed skin) drives a dermatologic workup; group II (normal skin) demands a systemic screen even when the patient looks well.
3. Is there a red-flag signature? Anaphylaxis features, target lesions with mucosal involvement, jaundice with confusion, B-symptoms with lymphadenopathy—escalate before you investigate further.
4. Re-take the drug history. Add over-the-counter, herbal, illicit and recent-discharge medications. Deprescribe the suspect when feasible.
5. Order the baseline panel. FBC with differential, U&E and eGFR, LFTs with bilirubin and ALP, ferritin, fasting glucose or HbA1c, TSH, HIV—plus chest X-ray and LDH if lymphoma is in the differential.
6. Treat what you can, layer relief while results return. Liberal emollients, cool environment, second-generation H1 blocker, short topical corticosteroid course where lesions exist.
7. Re-assess at 2–4 weeks. If undiagnosed, escalate to dermatology for biopsy/patch testing and to internal medicine for the systemic puzzle.
8. Refer urgently for cholestatic itch in pregnancy, suspected bullous pemphigoid, suspected lymphoma, refractory uraemic itch, immunosuppressed patients with new pruritic eruption and any patient meeting the do-not-miss criteria above.

↔On a small screen, swipe or scroll sideways to see the full table.

Rational management runs three rails simultaneously: treat the cause where one is identified, repair the skin barrier, and modulate itch transmission. Combining all three from the first visit shortens the time to relief and reduces the lichenification and prurigo that complicate chronic itch.

Universal foundation (every patient)

• Emollient regimen. Bland fragrance-free moisturisers applied liberally at least twice daily and immediately after bathing onto damp skin; thicker ointments overnight in dry climates and for older adults.
• Trigger removal. Soap substitutes instead of detergent bars; lukewarm short showers; cotton or smooth-fibre clothing; avoid wool next to skin; humidify in heated environments; cool the bedroom.
• Nail care. Short, smooth nails to limit excoriation damage; cotton gloves overnight when scratching dominates sleep.
• Behavioural strategies. Habit-reversal techniques, mindfulness, stress reduction; treat coexisting low mood and anxiety in parallel.

Topical anti-inflammatories

• Topical corticosteroid of appropriate potency: mild (hydrocortisone 1% face/flexures), moderate (mometasone, betamethasone valerate body), potent (clobetasol) for refractory body sites under specialist guidance. Step down once flare settles; avoid uninterrupted potent use on face, flexures and groin.
• Topical calcineurin inhibitor (tacrolimus 0.03–0.1% ointment, pimecrolimus 1% cream) for steroid-sparing maintenance, especially face, eyelids and intertriginous sites.
• Adjunct topicals: menthol, camphor, pramoxine, capsaicin (for localised neuropathic itch), polidocanol—evidence is modest but useful in selected niches.

Oral antihistamines (use with intention, not reflex)

• Second-generation H1 blockers: cetirizine 10 mg daily, loratadine 10 mg daily, fexofenadine 180 mg daily, bilastine 20 mg daily. First line for histaminergic itch (urticaria, atopic flares with prominent itch).
• Updosing: chronic spontaneous urticaria may require up to fourfold doses of a second-generation antihistamine under specialist direction before escalating to omalizumab.
• Sedating first-generation H1 blockers (hydroxyzine, diphenhydramine) only as short-term sleep aids—avoid in older adults, falls risk, prostatism, narrow-angle glaucoma and dementia.
• Avoid antihistamines as monotherapy for cholestatic, uraemic and neuropathic itch—they rarely help and waste the chance to use a more targeted agent.

Cause-specific systemic therapy

↔On a small screen, swipe or scroll sideways to see the full table.

Phototherapy and refractory pathways

Narrowband UVB phototherapy (typically 2–3 sessions per week for 6–12 weeks) is supported by long-standing evidence for atopic eczema, psoriasis, uraemic pruritus, polycythaemia-related itch and HIV-associated pruritus. It requires dermatology supervision, screening for photosensitising medication and counselling about cumulative skin cancer risk for prolonged courses. Refractory or undiagnosed chronic itch warrants combined dermatology and internal medicine input; palliative care expertise is invaluable for itch in advanced cancer or end-stage liver disease.

Pregnancy

Late-pregnancy itch deserves a low threshold for investigation. Intrahepatic cholestasis of pregnancy (ICP) classically begins after 28 weeks with itchy palms and soles, no rash, raised serum bile acids and modestly raised transaminases. Rising bile acids correlate with increased stillbirth, preterm birth and meconium passage—UK and international obstetric guidance escalates surveillance and considers planned birth from 35–37 weeks when bile acids exceed 100 micromol/L. Polymorphic eruption of pregnancy presents in primigravidas in the third trimester with itchy urticarial papules in striae sparing the umbilicus; pemphigoid gestationis presents with peri-umbilical urticarial plaques evolving to bullae and warrants dermatology and obstetrics co-management. Treatment uses pregnancy-safe options: emollients, mild–moderate topical corticosteroids, and chlorphenamine or loratadine when an antihistamine is needed; ursodeoxycholic acid is widely used for ICP itch though its impact on perinatal outcomes is modest.

Paediatric considerations

Atopic eczema dominates paediatric pruritus; treat with stepped emollients, topical corticosteroids of appropriate potency for short bursts, and topical calcineurin inhibitors for face and flexures over age 2. Scabies is common in nurseries and households; treat the index child plus all contacts simultaneously with permethrin 5% (single application, repeat at 7 days). Avoid sedating antihistamines in young children—clinical benefit is limited and behavioural side effects are common. Refer atypical patterns (severe early-onset eczema with infections—consider primary immunodeficiency, dermatitis herpetiformis with gluten exposure, urticaria pigmentosa with mastocytosis) to paediatric dermatology.

Older adults

Several drivers stack: xerosis cutis, polypharmacy (the average over-75 takes >5 medications), bullous pemphigoid in evolution, occult lymphoma or biliary disease, post-stroke central itch and depression-associated psychogenic itch. Anticholinergic burden from sedating antihistamines causes confusion, falls and urinary retention—use second-generation agents only or treat the underlying cause. Dialysis-associated pruritus is markedly more common in older adults and benefits from gabapentin titrated cautiously to renal function (often 100 mg post-dialysis to start) plus newer agents such as difelikefalin where access permits.

• Document objectively. Use a numerical rating scale (0–10) or visual analogue scale at each contact, plus sleep impact and work/school disruption; trends matter more than single snapshots.
• Photograph with consent. Date-stamped images of distribution and lesions help dermatology triage, especially for transient urticarial wheals or fluctuating eczematous flares.
• Reconcile medications carefully. A formal medication reconciliation at admission and discharge often surfaces ACE inhibitors, opioids and starches that have been quietly driving the itch.
• Coach the application technique. Patients routinely under-apply topical therapy; teach the fingertip unit (one fingertip = ~0.5 g, covers two adult palms) and demonstrate liberal emollient use during a structured medication administration teach.
• Avoid escalating steroids without diagnosis. A worsening rash on potent topicals is a classic clue that the diagnosis is wrong (crusted scabies, dermatitis herpetiformis, cutaneous lymphoma, contact allergy to the steroid base itself).
• Track titrations of gabapentinoids. Renal-adjust doses, watch for sedation and falls in older adults, document tolerance and effect at each visit, and avoid abrupt withdrawal.
• Plan handover meticulously. Use a structured nursing handoff: itch trajectory, current ladder, drug culprits suspected, next investigation due, escalation criteria.
• Refer early when red flags appear. Suspected lymphoma, refractory cholestatic itch, dermatology emergencies (SJS/TEN), pregnancy-related cholestasis and scabies outbreaks all warrant same-day specialist contact.

Vital signs and systemic check

• Routine vital signs with NEWS2 or local scoring at every contact—new tachycardia or hypotension in a pruritic patient may herald anaphylaxis or sepsis from secondary infection.
• Daily jaundice assessment and serial bilirubin trends in cholestatic itch.
• Temperature and excoriation surveillance—staphylococcal superinfection is the most common complication of chronic scratching.
• SpO₂, respiratory rate and conscious level when systemic features (anaphylaxis, sepsis, encephalopathy) are possible.

Itch-specific assessment

• Itch intensity 0–10, sleep disruption hours, scratching behaviour during the shift.
• Skin: distribution, primary vs secondary lesions, signs of secondary infection (weeping, golden crust, pustule, spreading erythema).
• Topical therapy adherence and technique check—observe one application during the shift.
• Mood, anxiety and impact on daily activities; screen for self-harm thoughts in severe refractory itch.

Red flags requiring escalation

• New angioedema, wheeze, hoarseness or syncope—activate anaphylaxis pathway.
• Mucosal involvement, target lesions, skin tenderness or sloughing—activate dermatology emergency pathway for SJS/TEN.
• New confusion, asterixis or coagulopathy in a patient with cholestatic itch—activate hepatology pathway.
• Spreading erythema with fever—suspect cellulitis from chronic scratching.
• Drenching night sweats, weight loss >10% over 6 months and palpable lymphadenopathy—urgent haematology referral.
• New uncontrolled itch on dialysis with rising potassium or worsening cardiovascular symptoms—coordinate with renal team.

Direct from chronic itch

• Lichenification, prurigo nodularis and post-inflammatory pigment change.
• Secondary bacterial infection (impetiginisation, cellulitis, abscess) and superficial fungal overlay in macerated areas.
• Sleep deprivation with daytime cognitive impairment, mood disorder, work and school dysfunction.
• Suicidal ideation in severe refractory cases—particularly in older adults with multifactorial itch.

From the underlying disease

• Hepatic failure trajectory, variceal bleeding and ascites in undiagnosed cholestasis or cirrhosis.
• Disease progression and missed early-stage lymphoma when itch is dismissed as “dry skin”.
• Worsening renal function and cardiovascular risk in poorly managed CKD-aP.
• Iatrogenic harm: anticholinergic side effects (falls, retention, delirium), sedation, gabapentinoid abuse and SCAR from high-risk drugs.

Many drivers are not preventable, but several are. Counsel atopic patients to maintain a daily emollient routine even when skin is clear—it reduces flare frequency. Hydrate the skin barrier in older adults during winter heating with thicker emollients and shorter, cooler showers. Review polypharmacy proactively in patients aged over 65 to deprescribe culprit ACE inhibitors, opioids and antihistamine cocktails when feasible. Optimise dialysis adequacy, mineral metabolism and emollient routines in CKD before reaching for systemic neuro-modulators. Vaccinate eligible patients against shingles to prevent post-herpetic itch. Treat scabies index cases promptly and contact-trace households and care homes to prevent outbreaks. And use the lowest effective potency of topical steroids for the shortest necessary period to limit skin atrophy and tachyphylaxis.

Outlook depends on cause. Acute drug-induced itch usually resolves within days to weeks of withdrawal. Atopic eczema often improves into adulthood but follows a relapsing course. Cholestatic itch frequently improves once the underlying cholestasis is addressed (e.g. ursodeoxycholic acid in PBC, delivery in ICP), although severe cases may persist and need a layered systemic approach. Uraemic itch tends to track dialysis adequacy and response to gabapentinoids or difelikefalin. Lymphoma-associated itch typically resolves with successful chemotherapy. Refractory chronic idiopathic pruritus carries a substantial quality-of-life burden and often needs combined dermatology, palliative care and mental health input—setting realistic expectations early and tracking objective measures (sleep, scratch behaviour, lesion surface) keeps treatment targeted.

Subtle deterioration

The pruritic patient who is silently getting worse rarely complains loudly. Watch for the cluster: nail-bed bruising from constant scratching, fingernails worn smooth, sheets stained with serous fluid in the morning, weight quietly dropping, and a sodium that has slipped or a bilirubin that has crept up. Pattern recognition reaches for a focused review and not just another tube of emollient.

Communication friction

Patients who have lived with chronic itch for years often feel dismissed; words like “just dry skin” or “it’s only itch” erode trust quickly. Acknowledge the impact, document the severity score and sleep impact, and outline a clear plan. Be honest when no cause has yet been found—the structured search continues and most patients can be helped, even if the itch is not fully eliminated.

Bedside checklist

• Strip all bedding, examine the whole skin in good light, then re-dress.
• Audit every medication including over-the-counter and herbal supplements at each shift change.
• Confirm emollient is at the bedside and a fingertip-unit demonstration has been given.
• Schedule the next investigation and review—open-ended waiting fuels distress.
• Loop in the next team via a structured handover with itch score, ladder step and culprit hypotheses.

Initial bundle: ABCDE primary survey, IV access, point-of-care glucose, lactate and venous blood gas. Send paired FBC, U&E, LFTs, coagulation, blood cultures and a serum tryptase if anaphylaxis is in the differential. Stop suspected culprit medications and document the timeline. Photograph lesions with consent. Activate dermatology, hepatology, haematology or critical care pathways as the picture evolves and never assume itch alone is benign in a haemodynamically unstable patient.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient assignment, ordered response, matrix matching and cloze completion on the topic of itchy skin (pruritus) workup, antihistamine choice, cholestatic and uraemic itch, and red-flag escalation—matched to Clinical Judgment Measurement Model layering of cues before action.